AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27734072 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban therapy initiated on the same day
Number of subjects: 401
Study 27734072 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban therapy delayed by one or more days
Number of subjects: 401
Study 25577176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) administration
Number of subjects: 23
Study 24772726 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic formulation containing Lactobacillus acidophilus LA-5 and Bifidobacterium BB-12
Number of subjects: 0
Study 24772726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17110467 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil with high phenolic content
Number of subjects: 182
Study 17110467 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil with medium phenolic content
Number of subjects: 182
Study 17110467 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil with low phenolic content
Number of subjects: 182
Study 15220012 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg QD initially, titrated to max 45 mg)
Number of subjects: 244
Study 15220012 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (2 mg QD initially, titrated to max 8 mg)
Number of subjects: 244
Study 11527474 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH administered subcutaneously daily at bedtime
Number of subjects: 31
Study 11527474 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH and a structured resistance exercise program
Number of subjects: 31
Study 11527474 — intervention group
Group type: COMPARATOR
Intervention: Structured resistance exercise with placebo injections
Number of subjects: 31
Study 11527474 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections only
Number of subjects: 31
Study 11527474 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined rhGH treated subjects
Number of subjects: 31
Study 9239456 — intervention group
Group type: EXPERIMENTAL
Intervention: Test patch (MenorestTM) at 37.5 micrograms E2/day
Number of subjects: 24
Study 9239456 — intervention group
Group type: EXPERIMENTAL
Intervention: Test patch (MenorestTM) at 50 micrograms E2/day
Number of subjects: 24
Study 9239456 — intervention group
Group type: EXPERIMENTAL
Intervention: Test patch (MenorestTM) at 75 micrograms E2/day
Number of subjects: 24
Study 9239456 — intervention group
Group type: COMPARATOR
Intervention: Reference patch at 50 micrograms E2/day
Number of subjects: 24
Study 8498761 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including foot-care education, behavioral contracts, and reminders.
Number of subjects: 352
Study 3102323 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (600 mg/100 ml) by enema
Number of subjects: 70
Study 3102323 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (20 mg/100 ml) by enema
Number of subjects: 70
Study 4932544 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride (200 mg daily)
Number of subjects: 54
Study 4932544 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 54
Study 31957417 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gel (CG gel)
Number of subjects: 30
Study 30418491 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Social Interaction (ESI) model
Number of subjects: 82
Study 27709225 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (20-week treatment)
Number of subjects: 79
Study 27709225 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (24-week treatment on top of metformin)
Number of subjects: 79
Study 27709225 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 79
Study 25257865 — intervention group
Group type: EXPERIMENTAL
Intervention: Skim milk (SM)
Number of subjects: 28
Study 25257865 — intervention group
Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 28
Study 25257865 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate‐electrolyte solution (CES)
Number of subjects: 28
Study 22094635 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM coadministered with routine vaccines
Number of subjects: 0
Study 22094635 — intervention group
Group type: COMPARATOR
Intervention: Routine vaccinations alone
Number of subjects: 0
Study 20301825 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-cm multiholed catheter
Number of subjects: 16
Study 20301825 — intervention group
Group type: COMPARATOR
Intervention: triple-orifice epidural catheter
Number of subjects: 16
Study 17709295 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg levetiracetam
Number of subjects: 45
Study 17709295 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg topiramate
Number of subjects: 45
Study 17709295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 16285598 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorations carried out immediately after bleaching (T0)
Number of subjects: 0
Study 16285598 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorations 7 days after bleaching (T7)
Number of subjects: 0
Study 16285598 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorations 14 days after bleaching (T14)
Number of subjects: 0
Study 16285598 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorations 21 days after bleaching (T21)
Number of subjects: 0
Study 16285598 — intervention group
Group type: COMPARATOR
Intervention: Control group - restorations in unbleached teeth (TC)
Number of subjects: 0
Study 12042580 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg for infants and 20 mg for older children)
Number of subjects: 0
Study 12042580 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 0
Study 10442852 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline (0.1-0.8 microg/min) with L-NMMA (3.0 mg/kg over 5 min, followed by 30 microg/kg/min over 75 min)
Number of subjects: 0
Study 10442852 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline (0.1-0.8 microg/min) with L-NMMA (6.0 mg/kg over 5 min, followed by 60 microg/kg/min over 75 min)
Number of subjects: 0
Study 10442852 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous endothelin-1 (ET-1; 5.0 ng/kg/min for 80 min)
Number of subjects: 0
Study 8674563 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g of Augmentin (co‐amoxiclav) i.v. at induction of anaesthesia
Number of subjects: 116
Study 8674563 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 116
Study 2190041 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil, 320 mg/day
Number of subjects: 27
Study 2190041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethmosine, 800 mg/day
Number of subjects: 27
Study 2190041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethacizine, 150 mg/day
Number of subjects: 27
Study 32799 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam (0.5, 1, 2, 4, 8 mg)
Number of subjects: 240
Study 32799 — intervention group
Group type: COMPARATOR
Intervention: Pentobarbital (100 mg)
Number of subjects: 240
Study 30916575 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk (Prolacta Bioscience, Duarte, CA) administered from day -3 until day +14 after BMT
Number of subjects: 46
Study 30916575 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (control group)
Number of subjects: 46
Study 28551058 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil-desflurane (REM-DES)
Number of subjects: 40
Study 28551058 — intervention group
Group type: COMPARATOR
Intervention: remifentanil-propofol (REM-PRO)
Number of subjects: 40
Study 28551058 — intervention group
Group type: COMPARATOR
Intervention: Both groups (REM-PRO and REM-DES)
Number of subjects: 40
Study 26264722 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking speed assessed by the Timed 25‐Foot Walk
Number of subjects: 52
Study 26264722 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 52
Study 26264722 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking (speed, endurance, dexterity)
Number of subjects: 52
Study 26264722 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment status
Number of subjects: 52
Study 26264722 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 52
Study 26264722 — intervention group
Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 52
Study 26264722 — intervention group
Group type: EXPERIMENTAL
Intervention: Unemployed participants
Number of subjects: 52
Study 24276097 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT) applied to open fractures in the 2008-2009 cohort.
Number of subjects: 0
Study 24276097 — intervention group
Group type: COMPARATOR
Intervention: Occlusive dressing applied to open fractures in the 2003-2004 cohort.
Number of subjects: 0
Study 21395905 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 150
Study 21395905 — intervention group
Group type: EXPERIMENTAL
Intervention: Proluton depot
Number of subjects: 150
Study 21395905 — intervention group
Group type: COMPARATOR
Intervention: Bed rest
Number of subjects: 150
Study 19731848 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 70% isopropyl alcohol (IPA)
Number of subjects: 85
Study 19731848 — intervention group
Group type: COMPARATOR
Intervention: IV promethazine
Number of subjects: 85
Study 17909211 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 0
Study 17909211 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 0
Study 17909211 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal muscle relaxants (for acute low back pain)
Number of subjects: 0
Study 17909211 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (for chronic low back pain)
Number of subjects: 0
Study 17909211 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 0
Study 17909211 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 0
Study 17909211 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 0
Study 17909211 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (for radiculopathy)
Number of subjects: 0
Study 17909211 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids
Number of subjects: 0
Study 15081650 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 403
Study 15081650 — intervention group
Group type: COMPARATOR
Intervention: Open resection
Number of subjects: 403
Study 11523603 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear approach (25 patients)
Number of subjects: 50
Study 11523603 — intervention group
Group type: COMPARATOR
Intervention: Focal approach (25 patients)
Number of subjects: 50
Study 9566477 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine, 150mg/day
Number of subjects: 81
Study 9566477 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram, 20mg/day
Number of subjects: 81
Study 9566477 — intervention group
Group type: COMPARATOR
Intervention: No pharmacological treatment (Control)
Number of subjects: 81
Study 9566477 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 81
Study 9566477 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 81
Study 7816261 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporin A (CsA) treatment at a mean dose of 3.23 mg/kg/day for 12 months
Number of subjects: 10
Study 7816261 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporin A (CsA) treatment
Number of subjects: 10
Study 2975147 — intervention group
Group type: COMPARATOR
Intervention: Thiopental alone (Control)
Number of subjects: 24
Study 2975147 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental and ketamine
Number of subjects: 24
Study 2975147 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental and isoflurane
Number of subjects: 24
Study 2975147 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental and NLA drugs
Number of subjects: 24
Study 31845487 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal masks (NM)
Number of subjects: 80
Study 31845487 — intervention group
Group type: COMPARATOR
Intervention: Nasal prongs (NP)
Number of subjects: 80
Study 28926296 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (100,000 IU, three doses, 12-hourly)
Number of subjects: 71
Study 28926296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 26924265 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU of vitamin D
Number of subjects: 60
Study 26924265 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU of vitamin D
Number of subjects: 60
Study 25796007 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy drinking (HD) group
Number of subjects: 38
Study 25796007 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 38
Study 25796007 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after one month of abstinence
Number of subjects: 38
Study 23073171 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated Linoleic Acid (CLA) supplementation (3g daily for 30 days)
Number of subjects: 18
Study 23073171 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC) supplementation (3g daily for 30 days)
Number of subjects: 18
Study 21626077 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) nicardipine initiated within 3 hours of onset of ICH and continued for the next 24 hours
Number of subjects: 1280
Study 21626077 — intervention group
Group type: COMPARATOR
Intervention: Standard SBP reduction to ≤180 mm Hg
Number of subjects: 1280
Study 18482628 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotropes
Number of subjects: 0
Study 18482628 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive medications
Number of subjects: 0
Study 18482628 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 0
Study 16634837 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐vitamins (50 mg thiaminhydrochlorid, 50 mg pyridoxine, and 0.05 mg cyanocobalamin), plus 5 mg folic acid daily for 6 weeks
Number of subjects: 65
Study 16634837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 16634837 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐vitamins
Number of subjects: 65
Study 12806859 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone treatment
Number of subjects: 0
Study 12806859 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone treatment
Number of subjects: 0
Study 12806859 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 0
Study 12806859 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative therapies
Number of subjects: 0
Study 12806859 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual risk profile assessment
Number of subjects: 0
Study 10877152 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐dihydroergocryptine
Number of subjects: 123
Study 10877152 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 123
Study 9663826 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous standard heparin (subcutaneous in two patients), adjusted to provide standard anticoagulant activity.
Number of subjects: 16
Study 9663826 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (second occasion during a relapse)
Number of subjects: 16
Study 9663826 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (general treatment)
Number of subjects: 16
Study 1541605 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 20
Study 1541605 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 20
Study 4011073 — intervention group
Group type: EXPERIMENTAL
Intervention: X-ray pelvimetry
Number of subjects: 200
Study 4011073 — intervention group
Group type: COMPARATOR
Intervention: No x-ray pelvimetry
Number of subjects: 200
Study 31924334 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg IV every 2 weeks until disease progression or intolerable toxicity
Number of subjects: 26
Study 31309968 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratings of Perceived Difficulty (RPD) scales
Number of subjects: 62
Study 31309968 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical RPD scale
Number of subjects: 62
Study 31309968 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural sway measures
Number of subjects: 62
Study 28292754 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 1764
Study 28292754 — intervention group
Group type: COMPARATOR
Intervention: ICD
Number of subjects: 1764
Study 25595195 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at PC6, HT7 and LR3 for 10 weeks
Number of subjects: 40
Study 25595195 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (no intervention initially)
Number of subjects: 40
Study 23250818 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (50,000 IU weekly for 12 months)
Number of subjects: 30
Study 23250818 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 30
Study 23250818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21883644 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP&D/P MPs
Number of subjects: 26
Study 21883644 — intervention group
Group type: COMPARATOR
Intervention: PRP and saline (control)
Number of subjects: 26
Study 19700934 — intervention group
Group type: EXPERIMENTAL
Intervention: Aeroneb-go (AE)
Number of subjects: 36
Study 19700934 — intervention group
Group type: EXPERIMENTAL
Intervention: Omron-NE-U22 (OM)
Number of subjects: 36
Study 19700934 — intervention group
Group type: EXPERIMENTAL
Intervention: Pari-eMotion (PA)
Number of subjects: 36
Study 17989384 — intervention group
Group type: EXPERIMENTAL
Intervention: Three cycles of MOPP-ABV plus involved-field radiotherapy
Number of subjects: 1538
Study 17989384 — intervention group
Group type: COMPARATOR
Intervention: Subtotal nodal radiotherapy alone
Number of subjects: 1538
Study 17989384 — intervention group
Group type: EXPERIMENTAL
Intervention: Six cycles of MOPP-ABV plus involved-field radiotherapy
Number of subjects: 1538
Study 17989384 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of MOPP-ABV plus involved-field radiotherapy
Number of subjects: 1538
Study 17989384 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of MOPP-ABV plus subtotal nodal radiotherapy
Number of subjects: 1538
Study 14519707 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (conjugated equine estrogen, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d)
Number of subjects: 16608
Study 14519707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16608
Study 14519707 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 16608
Study 10534147 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicinal herbs (seven pills containing a standardized preparation of 35 Chinese herbs, four daily doses for 6 months)
Number of subjects: 68
Study 10534147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 10534147 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicinal herbs
Number of subjects: 68
Study 8980932 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole/Amoxycillin (n = 11)
Number of subjects: 38
Study 8980932 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole/Amoxycillin/Metronidazole (n = 16)
Number of subjects: 38
Study 8980932 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal Bismuth Subcitrate/Amoxycillin/Metronidazole (n = 11)
Number of subjects: 38
Study 8980932 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 1 year
Number of subjects: 38
Study 8980932 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 2 years
Number of subjects: 38
Study 1871692 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 16
Study 1871692 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 16
Study 7159001 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 130
Study 7159001 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin-gentamycin combination
Number of subjects: 130
Study 6202746 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable fabric operating clothing (Barrier 450, Johnson & Johnson)
Number of subjects: 52
Study 6202746 — intervention group
Group type: COMPARATOR
Intervention: Conventional cotton clothing
Number of subjects: 52
Study 28345173 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% increase in step rate
Number of subjects: 32
Study 28345173 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% decrease in step rate
Number of subjects: 32
Study 28345173 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% change in step rate
Number of subjects: 32
Study 28345173 — intervention group
Group type: COMPARATOR
Intervention: Preferred step rate
Number of subjects: 32
Study 27466220 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 25
Study 27466220 — intervention group
Group type: COMPARATOR
Intervention: Pramipexole
Number of subjects: 25
Study 25571338 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine (α2-adrenergic agonist), administered over a 4-week program
Number of subjects: 0
Study 25571338 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline walking endurance
Number of subjects: 0
Study 22748458 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundle treatment
Number of subjects: 203
Study 19937077 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein group (LG)
Number of subjects: 64
Study 19937077 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh plug group (MPG)
Number of subjects: 64
Study 18195164 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (30% fat calories)
Number of subjects: 20
Study 18195164 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate diet (20 g of carbohydrates)
Number of subjects: 20
Study 16393753 — intervention group
Group type: EXPERIMENTAL
Intervention: Left emotional faces
Number of subjects: 5